恩威医药
(301331)
| 流通市值：8.74亿 | | | 总市值：26.67亿 |
| 流通股本：2298.28万 | | | 总股本：7013.84万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 221,123,205.57 | 236,120,514.71 | 326,840,054.92 | 328,540,328.1 |
| 应收票据及应收账款 | 97,802,419.1 | 93,095,689.67 | 103,264,412.59 | 98,620,500.98 |
| 应收账款 | 97,802,419.1 | 93,095,689.67 | 103,264,412.59 | 98,620,500.98 |
| 应收款项融资 | 179,348,477.51 | 171,900,424.39 | 120,867,968.08 | 142,736,414.3 |
| 预付款项 | 12,240,213.93 | 14,911,422.66 | 13,064,464.44 | 13,025,799.23 |
| 其他应收款合计 | 4,422,757.56 | 3,987,706.52 | 23,656,331.34 | 22,129,484.01 |
| 存货 | 127,608,315.47 | 107,367,067.33 | 114,622,398.52 | 123,475,292.18 |
| 其他流动资产 | 3,435,816.89 | 2,316,777.34 | 1,400 | 1,065,981.8 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 796,383,809.55 | 786,859,452.41 | 884,410,593.17 | 888,682,727.89 |
| 非流动资产: | | | | |
| 长期股权投资 | 373,989.35 | 373,989.35 | 363,697.36 | 356,142.66 |
| 投资性房地产 | 30,273,878.75 | 30,873,114.8 | 31,472,350.85 | 32,071,586.9 |
| 固定资产 | 216,489,627.12 | 220,638,376.27 | 221,879,356.34 | 227,573,049.42 |
| 在建工程 | 20,866,684.5 | 8,818,254.75 | 9,276,123.51 | 9,263,467.89 |
| 使用权资产 | 1,992,112.6 | 1,668,083.21 | - | - |
| 无形资产 | 144,015,648.53 | 148,043,809.24 | 38,052,766.96 | 39,396,193.21 |
| 开发支出 | - | - | 18,016,417.8 | - |
| 商誉 | 100,552,610.87 | 100,552,610.87 | 100,552,610.87 | 100,552,610.87 |
| 长期待摊费用 | 10,077,857.34 | 10,682,332.13 | 12,203,704.01 | 13,836,820.82 |
| 递延所得税资产 | 4,176,035.88 | 3,047,439.1 | 1,945,260.4 | 1,927,954.56 |
| 其他非流动资产 | 30,335,117.8 | 25,940,217.8 | 257,520 | 18,122,917.4 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 559,153,562.74 | 550,638,227.52 | 434,019,808.1 | 443,100,743.73 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,355,537,372.29 | 1,337,497,679.93 | 1,318,430,401.27 | 1,331,783,471.62 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 48,544,704.66 | 30,940,833.63 | 27,934,287.9 | 37,442,572.98 |
| 应付账款 | 48,544,704.66 | 30,940,833.63 | 27,934,287.9 | 37,442,572.98 |
| 合同负债 | 21,599,387.56 | 14,009,811.41 | 13,839,693.44 | 19,633,160.29 |
| 应付职工薪酬 | 33,538,642.2 | 39,942,277.75 | 35,676,527.55 | 37,741,787.91 |
| 应交税费 | 11,131,110.35 | 17,313,965.77 | 12,487,662.83 | 11,034,727.26 |
| 其他应付款合计 | 100,259,696.87 | 104,862,634.13 | 88,289,555.74 | 93,331,100.96 |
| 一年内到期的非流动负债 | 1,284,619.36 | 882,307.48 | - | - |
| 其他流动负债 | 2,807,920.39 | 1,821,275.49 | 1,799,160.14 | 2,552,310.83 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 219,166,081.39 | 209,773,105.66 | 180,026,887.6 | 201,735,660.23 |
| 非流动负债: | | | | |
| 长期借款 | 33,000,000 | - | - | - |
| 租赁负债 | - | 455,192.28 | - | - |
| 递延收益 | 11,347,108.91 | 11,915,031.74 | 12,364,444.95 | 12,925,588.92 |
| 递延所得税负债 | 12,472,198.62 | 12,168,443.84 | 12,322,136.43 | 12,378,238.37 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 56,819,307.53 | 24,538,667.86 | 24,686,581.38 | 25,303,827.29 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 275,985,388.92 | 234,311,773.52 | 204,713,468.98 | 227,039,487.52 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 70,138,359 | 70,138,359 | 70,138,359 | 70,138,359 |
| 资本公积 | 679,401,313.29 | 671,508,200.79 | 664,633,600.79 | 664,633,600.79 |
| 减:库存股 | 70,733,876.51 | 30,782,910.98 | - | - |
| 盈余公积 | 35,069,179.5 | 35,069,179.5 | 35,069,179.5 | 35,069,179.5 |
| 未分配利润 | 365,677,008.09 | 357,253,078.1 | 343,875,793 | 334,902,844.81 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,079,551,983.37 | 1,103,185,906.41 | 1,113,716,932.29 | 1,104,743,984.1 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,079,551,983.37 | 1,103,185,906.41 | 1,113,716,932.29 | 1,104,743,984.1 |
| 负债和股东权益合计 | 1,355,537,372.29 | 1,337,497,679.93 | 1,318,430,401.27 | 1,331,783,471.62 |
| 公告日期 | 2024-04-22 | 2024-04-22 | 2023-10-27 | 2023-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |